各种针对特定分子的生物制剂为各种肿瘤治疗提供了新的选择。丘疹丘疹型药物皮疹是这些制剂非常常见的皮肤反应。虽然不危及生命，但丘疹丘疹型药物皮疹可能影响患者的情感和社交生活，并在极少数情况下导致抗癌治疗中断。本研究的目的是回顾分子靶向制剂诱导的丘疹丘疹型药物皮疹的发生率、临床特征、病理机制和当前治疗方案。该审查通过PubMed、Embase和Cochrane搜寻“丘疹丘疹型药物皮疹”、“丘疹脓疱性皮疹”或“类似于痤疮的皮疹”和“皮肤毒性”、“皮肤毒性”、“皮肤反应”、“皮肤毒性”、“靶向治疗”或“药物治疗”等术语进行。在73个匹配我们的搜索条件的文章中，61篇是原创文章，12篇是病例报告或病例系列。丘疹丘疹型药物皮疹最常见于接受表皮生长因子受体抑制剂和丝裂原激活蛋白激酶抑制剂治疗的患者。典型的病变包括红色丘疹和脓疱，没有粉刺，伴随着灼热、瘙痒或皮肤干燥。病理机制涉及毛囊上皮的炎症和异常，在其中EGFR信号障碍发挥关键作用。丘疹丘疹型药物皮疹的治疗取决于皮疹的严重程度。及早识别和有效管理这种皮肤不良反应可以防止不必要的药物剂量减少和停用，改善患者的生存率和生活质量。癌症专家和皮肤科医生的密切合作对于优化治疗和提高患者的生存率非常重要。©2023 Wiley期刊LLC发表的美容皮肤学杂志。

Various biologic agents targeting specific molecules present new treatment options for various tumors. Acneiform eruption is a very common skin reaction to these agents. Although not life-threatening, acneiform eruption can affect patients' emotional and social lives. In very exceptional cases, it can lead to cancer therapy interruption.The aim of this study was to review the incidence rate, clinical characteristics, pathogenesis, and current management of acneiform eruption induced by molecularly targeted agents.This review was carried out through PubMed, Embase, and Cochrane searching terms 'acneiform eruption', 'papulopustular eruption' or 'acne-like rash' and 'skin toxicity', 'cutaneous toxicity', 'skin reactions', 'dermatological toxicities', 'target therapy,' or 'drug therapy'.Of the 73 articles matched our search terms, 61 were original articles and 12 were case reports or case series. Acneiform eruption is most commonly observed in patients treated with epidermal growth factor receptor inhibitors and mitogen-activated protein kinase inhibitors. Typical lesions consist of erythematous papules and pustules without comedones, accompanying with burning, pruritus, or xerosis. The pathogenesis involves inflammation and abnormalities of the follicular epithelium, where a disorder in EGFR signaling plays a key role. The treatment of acneiform eruption depends on the severity of the rash.Early recognition and effective management of this cutaneous adverse reaction can prevent unnecessary reduction and discontinuation of drug use and improve patient survival and quality of life. Close collaboration between oncologists and dermatologists is important to optimize therapy and improve patient survival.© 2023 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.